Company intelligence / Profile preview
Spruce Biosciences, Inc.
South San Francisco, California, USAsprucebio.com ↗
- Ownership
- Public · SPRB
- Employees
- ~50
- Development stage
- Other
01
Overview
The company has experienced mixed clinical results. Their lead candidate tildacerfont failed in two Phase 2 trials for CAH in 2024 and has been discontinued. They have acquired tralesinidase alfa (TA-ERT) for MPS IIIB, which has shown promising results in normalizing HS and HS-NRE levels over a five-year period, with plans to submit a BLA in 2026.
- Therapeutic areas
- PsychiatryEndocrinologyWomen's HealthRare DiseasesNeurology
- Modalities
- Small moleculesBiologicsEnzyme replacement therapy
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
HMNC (for MDD program)Kaken Pharmaceutical Co. Ltd.
04
Financials
- Market cap
- $122.7M
- Total revenue
- $0
- Enterprise value
- $34.1M
Beyond the preview
Go deeper on Spruce Biosciences, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Spruce Biosciences, Inc..